Arkolith/Insider Trading/LYEL/Form 4

ARCH Venture Partners IX Overage, L.P.

10% OwnerLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Mar 9, 2026
Net Buying
Open-Market Buys
$12.5M
Open-Market Sells
$0
Net Open-Market Flow
$12.5M
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 6, 2026Buy(P)488K$25.61$12.5M1.4M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001012975-26-000235) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML